health
InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines
BEIJING, Sept. 24, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Company has entered into a strategic research collaboration and license agreement with Eli Lilly and Company (“Lilly”) to develop new medicines.
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories
Dad says he went permanently blind
New York Post
I'm a woman in my 20s and I'm not have the sex I want. I know what's holding me back.
Slate
Millions of cancer cases are linked to 5 common infections: study
New York Post
45-year-old man died after ER sent him home without antibiotics, lawsuit says
OregonLive.com
19 Harmless Symptoms That Are Major Medical Red Flags
BuzzFeed